Patent search ap:("Janssen Biotech Page Inc.") AND inv:"Ricardo Attar"

11.

发明申请
Cysteine Engineered Fibronectin Type III Domain Binding Molecules 审中-公开

公开(公告)号：US20170362301A1

公开(公告)日：2017-12-21

申请号：US15629090

申请日：2017-06-21

Applicant: Janssen Biotech, Inc.

Inventor： Mark Anderson , Ricardo Attar , Michael Diem , Linus Hyun , Alastair King , Steven Jacobs , Shalom Goldberg , Donna Klein , Sheri Moores , Karyn O'Neil , Kristen Picha

IPC: C07K14/78

Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

12.

发明申请
EGFR and C-Met Fibronectin Type III Domain Binding Molecules 审中-公开

公开(公告)号：US20170305997A1

公开(公告)日：2017-10-26

申请号：US15637276

申请日：2017-06-29

Applicant: Janssen Biotech, Inc.

Inventor： Mark Anderson , Ricardo Attar , Michael Diem , Linus Hyun , Steven Jacobs , Alastair King , Donna Klein , Sheri Moores , Karyn O'Neil , Kristen Picha

IPC: C07K14/78 , A61K45/06 , C07K14/47 , C07K14/71 , C07K16/28 , C07K14/705 , A61K39/00 , A61K38/00

CPC classification number: C07K14/78 , A61K38/00 , A61K45/06 , A61K2039/505 , C07K14/47 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K2317/31 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2318/20 , C07K2319/70

Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

13.

发明授权
Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof 有权

公开(公告)号：US11884722B2

公开(公告)日：2024-01-30

申请号：US18157800

申请日：2023-01-20

Applicant: Janssen Biotech, Inc.

Inventor： Ricardo Attar , Francois Gaudet , Mark Tornetta , Alexey Teplyakov , Mark Mendonca , Suzanne Edavettal , Kodandaram Pillarisetti , Nathan Majewski , Yingzhe Li , Leopoldo L. Luistro, III , Diana Chin

IPC: A61K39/395 , C07K16/28 , A61K39/00

CPC classification number: C07K16/28 , A61K39/0011 , C07K16/2809 , A61K2039/505 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2317/94

Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.

14.

发明申请
EGFR and C-Met Fibronectin Type III Domain Binding Molecules 有权

公开(公告)号：US20210206825A1

公开(公告)日：2021-07-08

申请号：US17174524

申请日：2021-02-12

Applicant: Janssen Biotech, Inc.

Inventor： Mark Anderson , Ricardo Attar , Michael Diem , Linus Hyun , Steven Jacobs , Alastair King , Donna Klein , Sheri Moores , Karyn O'Neil , Kristen Picha

IPC: C07K14/705 , C07K14/78 , C07K14/71 , C07K16/28 , C07K14/47

Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

15.

发明申请
BLOCKING CD38 USING ANTI-CD38 F(ab')2 TO PROTECT NK CELLS 审中-公开

公开(公告)号：US20180208669A1

公开(公告)日：2018-07-26

申请号：US15319344

申请日：2015-06-15

Applicant: The United State of America, as represented by the Secretary Dept. of Health and Human Services , Janssen Biotech, Inc.

Inventor： Richard W. Childs , Maria Berg , Luis Espinoza Calderon , Kate Sasser , Ricardo Attar

IPC: C07K16/28 , A61P35/02 , A61P37/00

CPC classification number: C07K16/2896 , A61K39/39558 , A61P35/02 , A61P37/00 , C07K2317/21 , C07K2317/54 , C07K2317/73 , C07K2317/732 , A61K2300/00

Abstract: Provided herein are methods of inhibiting growth or proliferation of cells expressing CD38 by contacting the CD38-expressing cells with 1) NK cells bound to an anti-CD38 F(ab′)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously. Also provided herein are methods of treating or inhibiting a hyperproliferative disorder or an autoimmune disorder in a subject by administering to the subject 1) NK cells bound to an anti-CD38 F(ab′)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously.